Can-Fite Biopharma Announced It Published An Article In The Experimental And Therapeutic Medicine Journal, "Long-term Complete Response To Namodenoson In Liver Cancer With Child-Pugh B Cirrhosis
Can-Fite Biopharma Announced It Published An Article In The Experimental And Therapeutic Medicine Journal, "Long-term Complete Response To Namodenoson In Liver Cancer With Child-Pugh B Cirrhosis
Can-Fite Biopharma宣佈在《實驗與治療醫學》雜誌上發表了一篇文章，“對Child-Pugh B肝硬化肝癌中的納莫德諾松的長期全面反應
The Patient Participated In The Phase Ii Liver Cancer Study And Has Been Treated With Namodenoson For >7 Years Under Compassionate Use Program
該患者參與了II期肝癌研究，並根據同情使用計劃接受了Namodenoson的治療超過7年
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。